News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novozymes Biopharma Announces New Data Highlighting Potential For Monthly Drug Dosing


1/27/2014 10:32:10 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Copenhagen, Denmark – 27 January 2014 – Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced new data on extending the serum half-life of albumin in vivo. This compelling data set, recently presented at PepTalk 2014, demonstrates the potential of the company's half-life extension platform to deliver greater control of the therapeutic half-life of drug candidates, while showing how the technology can introduce the possibility for monthly dosing.

"This data represents the most promising insight yet that Novozymes' half-life extension technology delivers the reduction in dosing frequency that we set out to deliver when we began developing the platform five years ago," comments Dermot Pearson, Marketing Director at Novozymes Biopharma. He continues, "The level of excitement expressed by our customers in response to these achievements has been exceptional and we look forward to sharing our latest findings with wider industry experts who can benefit from this leading-edge data."

Through the modification of the human albumin molecule, Novozymes has altered the affinity of albumin to the FcRn receptor and has been able to demonstrate extended serum half-life of a range of albumin variants in vivo. The innovative technology provides drug developers with an attractive approach for optimizing the serum half-life of biopharmaceuticals. Already demonstrated in the fields of diabetes, hemophilia and neutropenia, the platform offers the potential to enhance patient quality of life through tailoring drug circulatory half-life to meet specific medical needs, while contributing improvements in compliance and healthcare costs.

A presentation on the new data can be downloaded from the posters and presentation section in the Information Centre at www.biopharma.novozymes.com

About Novozymes

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, they create tomorrow’s industrial biosolutions, improving their customers' business and the use of our planet's resources. Novozymes Biopharma develops and manufactures high-quality, safe, biological based ingredients and technologies to provide pharmaceutical and medical device manufacturers the knowledge-based solutions needed to address the challenges in developing innovative, safer, and more consistent final products. By combining their unique knowledge around recombinant albumin, half-life extension and hyaluronic acid with the specific application knowledge of their customers, Novozymes is committed to working with companies to deliver improved performance and safety for next-generation of medical device and pharmaceutical products. Read more at www.novozymes.com.

Contact:
Novozymes Biopharma:
Sally Vernon, Marketing Communications Manager
Email:SYKE@novozymes.com>
Tel. +44 115 955 3355

MEDIA CONTACTS
Europe
René Tronborg
Office: +45 4446 2274
Mobile: +45 3077 2274
retr@novozymes.com

China
Zhu Xiaoqing
Office: +86 106 298 7888+362
Mobile: +86 138 012 40590
xqzh@novozymes.com

US
Paige Donnelly
Office: +1 919 494 3209
Mobile: +1 919 218 4501
pagd@novozymes.com

Brazil
Ana Cecilia Amarante de Oliveira
Office: +55 41 3641 1096
Mobile: +55 41 9619 7594
aaov@novozymes.com

INVESTOR CONTACTS
US
Thomas Steenbech Bomhoff
Mobile: +1 919 649 2565
tsbm@novozymes.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES